No studies of dietary vitamin D intake and vitamin D receptor (VDR) have been conducted comparing breast risk among Hispanic women and non-Hispanic white (NHW) women. We investigated the association between vitamin D intake and breast cancer in a population-based case-control study of 1,527 NHW and 791 Hispanic breast cancer cases diagnosed in 1999-2004 in Arizona, New Mexico, Utah, and Colorado, and 1,599 NHW and 922 Hispanic age-matched controls. Vitamin D intake was assessed using food frequency questionnaires, and associations with breast cancer were adjusted for age, ethnicity, state, education, body mass index, smoking, age at menarche, age at first birth, parity, hormone exposure, height, and physical activity using logistic regression. BsmI, Poly A and FokI vitamin D receptor (VDR) genotypes were also measured. Dietary vitamin D intake was positively associated with breast cancer (highest vs. lowest quartile (Q (4) vs. Q (1)): odds ratio (OR) = 1.35, 95% confidence interval (CI) = 1.15-1.60; P (trend) = 0.003), whereas vitamin D supplement use was inversely associated with breast cancer (10+ μg/day vs. none: OR = 0.79, 95% CI = 0.65-0.96, P (trend) = 0.01). Similar patterns in risk were observed by ethnicity and menopausal status. Positive associations with dietary vitamin D intake and inverse associations with supplement use were observed for ER+/PR+ and ER-/PR- breast cancers, but not for ER+/PR- disease. BsmI genotype significantly modified the association between dietary vitamin D and breast cancer overall. Future research is needed to better understand potential differences in breast cancer risk by vitamin D source and hormone receptor status.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3390020 | PMC |
http://dx.doi.org/10.1007/s10549-011-1885-4 | DOI Listing |
Br J Surg
December 2024
Department of Breast Surgery, Worcestershire Acute Hospitals NHS Trust, Worcester, UK.
Phyllodes tumours of the breast are rare fibroepithelial neoplasms classified histologically into benign, borderline, or malignant; each requiring different treatment strategies. The infrequency of presentation can result in diagnostic and management variability. The aim is to provide evidence-based or expert consensus recommendations for multidisciplinary teams managing patients with phyllodes tumours.
View Article and Find Full Text PDFChemMedChem
January 2025
Federal University of Parana: Universidade Federal do Parana, Graduate Program in Pharmaceutical Sciences, BRAZIL.
The breast cancer resistance protein (BCRP/ABCG2) plays a major role in the multidrug resistance of cancers toward chemotherapeutic treatments. It was demonstrated that cholesterol regulates the ABCG2 activity, suggesting that lower levels of membrane cholesterol decrease the ABCG2 activity in mammalian cells. However, the precise mechanism remains unclear.
View Article and Find Full Text PDFCancer Res Commun
January 2025
University Hospitals Leuven, Leuven, Belgium.
This study evaluated the association between age at first full-term pregnancy (FFTP) and mammographic breast density (MBD) in postmenopausal women. 1,034 women, age 50-69y, were recruited from the Flemish (Belgium) population-based breast cancer screening program. Participants completed a questionnaire on lifestyle and reproductive factors.
View Article and Find Full Text PDFRadiol Case Rep
March 2025
Longstreet Clinic, Breast Surgery, 725 Jesse Jewell Parkway, Gainesville, GA 30501 USA.
Adenoid cystic carcinoma (ACC) of the breast is an exceptionally rare malignancy, accounting for less than 0.1% of all breast cancers. Despite its favorable prognosis, optimal management remains undefined due to its rarity and lack of consensus guidelines.
View Article and Find Full Text PDFOnco Targets Ther
January 2025
Affiliated Yongkang First People's Hospital and School of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China.
Background: TiaoShenGongJian (TSGJ) decoction, a traditional Chinese medicine for breast cancer, has unknown active compounds, targets, and mechanisms. This study identifies TSGJ's key targets and compounds for breast cancer treatment through network pharmacology, machine learning, and experimental validation.
Methods: Bioactive components and targets of TSGJ were identified from the TCMSP database, and breast cancer-related targets from GeneCards, PharmGkb, and RNA-seq datasets.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!